Notes

The amusing present: Even really nice compared to 40 years in the past. Uncanonical expression along with roles of HCN/f channels all over the system.
Conclusions The large-calibre transanal drainage tube effectively prevented the occurrence of anastomotic leakage after anterior resection for rectal cancer and increased the safety of the surgery.Purpose To detect the expressions of CD74 and matrix metalloproteinase-9 (MMP-9) in colon adenocarcinomas, and to explore the relationship between the expressions and clinicopathological characteristics and prognosis. Methods 98 cases of colon adenocarcinoma tissues from patients who underwent colon cancer resection in the Sixth Affiliated Hospital, Sun Yat-sen University from January 2013 to March 2015 comprised the experimental group, while 71 cases of colon mucosa tissues from patients who underwent colon polypectomy during the same period comprised the control group. qRT-PCR was used to detect the expressions of CD44 and MMP-9 mRNAs in the two groups, in order to analyze their correlation in colon adenocarcinomas, and to also analyze their relationship with clinicopathological characteristics and prognosis. Results The expressions of CD74 and MMP-9 mRNAs in colon adenocarcinoma tissues were significantly higher than those in normal colon mucosa tissues (p0.05), but had significant correlation with lymph node metastasis and pathological stage (p less then 0.05). According to the average expressions of CD74 and MMP-9 mRNAs, the patients were divided into low and high expression groups. The 3-year survival rate of patients in the low expression group was significantly higher than that in the high expression group (p less then 0.05). Moreover, the expressions of CD74 and MMP-9 were positively correlated (r = 0.853, p less then 0.001). Conclusion CD74 and MMP-9 are highly expressed in colon adenocarcinomas, and their expressions are closely related to the pathological stage, lymph node metastasis and prognosis of colon adenocarcinoma patients. Therefore, they can be used as important biological markers for diagnosis and prognosis prediction of colon adenocarcinoma.Purpose KRAS mutations are associated with colorectal cancer survival whereas the role of body mass index (BMI) is less defined. Phase angle, which is more an indicator of cell integrity also has not been studied as prognostic and predictive factor. We evaluated the association between BMI, phase angle and colorectal cancer overall survival (OS), by KRAS mutation status and other prognostic for metastatic colorectal cancer. Methods This prospective study included 89 patients diagnosed with metastatic colorectal cancer in oncology and pathology departments. BMI and phase angle alpha were reported from the TANITA MC-780U mutifrequency segmental body composition analyzer at presentation at our department. KRAS mutation status was analyzed. Multivariate analysis was estimated from Cox proportional hazards models. Results High phase angle which indicated proper cell integrity was associated with good performance status, low T stage, low fat percent and high BMI. Overall response was statistically significant with left sided colon cancer and high BMI. On multivariate analysis, the factors maintaining statistical significance with OS were KRAS and overall response. High BMI was associated with higher OS in both mutated and wild groups without statistical significance. ALLN cell line As regard progression-free survival (PFS), surgery, T stage, and lymphovascular invasion maintained statistical significance on multivariate analysis. Conclusion High phase angle was associated with improved performance status. High BMI was associated with improved OS in all KRAS subgroups.Purpose This study aimed to verify whether the regulation of miR-21 expression by lncRNA MALAT1 interferes with the biological behavior and mechanism of colon cancer cells. Methods RT-qPCR was used to detect the expression of MALAT1 in colon cancer and paracancerous tissues and different colon cancer cell lines (HT-29, SW480, SW620, CaCo-2). The relationship between MALAT1 and clinicopathological parameters of colon cancer patients and the interaction of MALAT1 and miR-21 by dual luciferase reporter gene detection were detected. Transwell invasion assay detected the invasive ability of colon cancer cells after MALAT1 inhibition and scratch assay detected the migration ability of colon cancer cells after MALAT1 inhibition. Subcutaneous tumor formation was detected in nude mice to measure the inhibition of the tumor size and volume of MALAT1 colon cancer cells. Results Compared with paracancerous tissues, MALAT1 expression was significantly increased in colon cancer tissues. MALAT1 expression was the highest in HT-29 colon cancer cell line. MALAT1 was specifically bound to miR-21 3' UTR. Inhibition of MALAT1 could inhibit colon cancer cell invasion and migration ability, and tumor formation in nude mice showed that the tumor volume and weight of the tumor-bearing mice were reduced after inhibiting the expression of MALAT1. Conclusion In conclusion, lncRNA MALAT1 plays an important role in the development of colon cancer. MALAT1 can regulate miR-21 to regulate the migration and invasion of colon cancer cells.Purpose The purpose of this study was to compare the long-term outcomes of laparoscopic and open sphincter-preserving total mesorectal excision (TME) for low rectal cancer (LRC) using propensity score matching (PSM). Methods The clinical and follow-up data of 169 patients with LRC who underwent sphincter-preserving TME at our institution between January 2011 and January 2014 were retrospectively analyzed. Patients were divided into laparoscopic and open group based on the surgical approach. PSM including age, sex, body mass index, clinical stage, and American Society of Anesthesiologists score with a 11 ratio was subsequently performed. Sixty-eight patients in each group were ultimately included, and short- and long-term outcomes were compared between groups. Results Compared with the open group, the laparoscopic group had less intraoperative blood loss, more rapid postoperative recovery, and lower incidence of 30-day postoperative complications. However, there were no significant differences in severity of postoperative 30-day complications between the two groups. Both groups had no intraoperative or 30-day postoperative mortality. Regarding survival outcome, tumor recurrence rate, tumor recurrence site, 5-year overall survival, and 5-year disease-free survival, there were no significant differences between groups. Conclusion Laparoscopic sphincter-preserving TME can achieve long-term outcomes similar to those of open TME for LRC.Purpose Chronic cholecystitis is a common inflammatory disease of the gallbladder. It is related with various gastrointestinal tumors, although its pathogenesis is not clear. This study was designed to investigate the association between chronic cholecystitis and the survival of patients with advanced colorectal cancer (CRC). Methods We conducted a population-based large-scale retrospective case-control study involving 1094 patients with advanced CRC, 286 patients with cholecystitis, and 808 without. The patients were admitted in two hospitals in China. Data were obtained from a patient survey by professional interviewers in addition to medical records. The statistical significance was estimated by Kaplan-Mayer analysis and Cox proportional hazard regression. Results The chronic cholecystitis group had a shorter survival time than non- cholecystitis group (HR for Nanfang hospital patients 0.638, 95%CI 0.457-0.890, p=0.008; HR for Changzhou No.2 hospital patients 0.583, 95%CI 0.433-0.787, p less then 0.001). Surgery and chemotherapy could prolong the survival of patients CRC and reduce their mortality (surgery HR for Nanfang hospital patients 1.638, 95%CI 1.087-2.469, p=0.018; HR for Changzhou No.2 hospital patients 2.137, 95%CI 1.399-3.265, p less then 0.001; chemotherapy HR for Nanfang hospital patients 1.766, 95%CI 1.238-2.518, p=0.002; HR for Changzhou No.2 hospital patients 2.616, 95%CI 1.816-3.768. p less then 0.001). The higher the TNM staging, the shorter the survival time (TNM staging HR for Nanfang hospital patients 3.912, 95%CI 3.201-4.781, p less then 0.001; HR for Changzhou No.2 hospital patients 3.907, 95%CI 3.05-5.005, p less then 0.001). Conclusion Cholecystitis was strongly associated with a poor long-term prognosis for patients with CRC. The results suggest that special attention to gallbladder inflammation might be needed during the treatment of CRC.Purpose This study was undertaken with a purpose to examine the anticancer effects of Lupane against human colorectal cancer. Methods The SW48 colorectal cell line and CDD18Co normal colon cell line were used in this study. The CCK8 assay was used to determine cell proliferation while acridine orange (AO)/ethidium bromide (EB) and DAPI staining assays were used to detect apoptosis. Wound healing and transwell assays were used to detect the cell migration and invasion. Western blotting was used to determine protein expression. Results Lupane inhibited the proliferation of colorectal cancer cells and the level of inhibition followed dose-dependent pattern. The antiproliferative role of Lupane was exerted via induction of apoptotic cell death. Western blot showed that the expression of Bcl-2 was decreased and that of Bax was increaced. Lupane also prompted the autophagy of the SW48 colorectal cancer cells and enhanced the expression of LC3-II. However, the expression of p62 was depleted. The treatment of Lupane also resulted to inhibition of the migratory potential of cancer cells as revealed by the wound healing assay. The invasion of SW48 cancer cells was also suppressed and was associated with suppression of metalloproteinase-9 (MMP-9) expression. Conclusion The results indicate the anticancer potential of Lupane against the colorectal cancer growth and propagation. The study envisages the importance of natural compounds for their usage against human cancers.Purpose Bevacizumab or cetuximab represent the standard treatment in association with classical chemotherapy in confirmed metastatic colorectal cancer (mCRC). Bevacizumab could be continued after the first disease progression with an overall survival (OS) advantage, compared to chemotherapy alone, but the optimal dose remains a debatable issue. Methods In a retrospective analysis of mCRC patients treated with bevacizumab, we selected patients with administration beyond progression, and stratified them according to the dose received- same dose bevacizumab (SDB) as first-line chemotherapy or double dose bevacizumab (DDB). For each group we evaluated OS, time to treatment failure (TTF) and progression-free survival in the first-line (PFS1) and in the second-line (PFS2). Results In the first-line therapy, oxaliplatin backbone regimen was used in 73% SDB, compared with 22.5% DDB patients, while irinotecan was used in 75% DDB and 27% SDB patients. Second-line oxaliplatin was given to 50% DDB and 29.7% SDB patients, while irinotecan was administered to 47.5% DDB and 70.3% SDB patients. The median values were OS - 41 months in the DDB group and 25 months in the SDB group (p = 0.01); TTF - 24 months in the DDB group and 19 months in the SDB group (p=0.009); PFS1 - 17 months in the DDB group and 12 months in the SDB group (p=0.008); PFS2 - 9 months in the DDB group and 5 months in the SDB group (p = 0.03). Conclusions Doubling the dose of bevacizumab at progression seems to provide OS and PFS advantage for mCRC patients.
Homepage: https://www.selleckchem.com/products/mg-101-alln.html